Revision date: 31 May 2016 Version: 2.0



## SPIRONOLACTONE TABLETS

## SAFETY DATA SHEET

according to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY

#### **Product Identifier**

**Product name:** Spironolactone Tablets

Synonyms: Spironolactone Tablets, USP; Spironolactone Tablets 25 mg; Spironolactone Tablets 50 mg; Spironolactone Tablets

100 mg

## **Intended Use of the Product**

Use of the substance/mixture: Pharmaceutical. Use only as directed. Refer to product insert for usage instructions and product information

## Name, Address, and Telephone of the Responsible Party

#### Supplier:

Mylan N.V.

Building 4

Trident Place

Mosquito Way

Hatfield

Hertfordshire

AL10 9UL

United Kingdom

www.mylan.com

+44 (0)1707 853000

#### **Emergency Telephone Number**

**Emergency number** 

: For Hazardous Materials Incident Spill, Leak, Fire, Exposure, or Accident Call CHEMTREC (24 Hours) Worldwide +1 703-741-5970

For adverse health events call: +1 877-446-3679

## 2. HAZARDS IDENTIFICATION

**Patients/Consumers:** Please refer to the product information insert or product label for appropriate consumer-specific information about this product when used according to the physician's directions. Pharmaceutical Agent – Handling of this product in its final form presents minimal occupational exposure risk.

This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and by Canada's Food and Drugs Act. It is in solid, final form for direct administration to the patient. Therefore, is it exempt from the US 2012 Hazard Communication Standard, as defined in the 29 CFR 1910.1200(b)(5)(iii) and in Canada's Hazardous Products Act.

## COMPOSITION/INFORMATION ON INGREDIENTS

#### **Mixture**

3.

This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and by Canada's Food and Drugs Act. It is in solid, final form for direct administration to the patient. Therefore, is it exempt from the US 2012 Hazard Communication Standard, as defined in the 29 CFR 1910.1200(b)(5)(iii) and in Canada's Hazardous Products Act.

Name	Product identifier	% (w/w)	Classification (GHS-US)
Calcium sulfate dihydrate	(CAS No) 10101-41-4	30 - 40	Not classified
Spironolactone	(CAS No) 52-01-7	10 - 20	Not classified
Silica, amorphous	(CAS No) 7631-86-9	0.5 - 1.5	Not classified

EN (English US) 1/5

Full text of H-phrases: see section 16

## 4. FIRST AID MEASURES

#### **Description of First Aid Measures**

**General:** Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label where possible).

**Inhalation:** The risk of inhalation exposure is negligible when product is in its final packaged form. If exposed and become symptomatic, move to fresh air and get medical attention if symptoms persist.

**Skin Contact:** Basic hygiene and appropriate precautions should prevent skin contact. If skin contact occurs, wash affected area with soap and water for at least 15 minutes. Should skin irritation, allergic reaction, or rash occur, remove contaminated clothing (if required) and seek medical advice.

**Eye Contact:** The risk of eye exposure is negligible when product is in its final packaged form. If eye contact occurs, flush immediately with water for at least 15 minutes. If easy to do, remove contact lenses. Get medical attention.

**Ingestion:** Ingestion is not an anticipated route of exposure. If accidental ingestion occurs, flush mouth out with water and get medical attention.

## Most Important Symptoms and Effects Both Acute and Delayed

**General:** Please refer to the package insert for more detailed information.

**Inhalation:** None expected under normal conditions of use. **Skin Contact:** None expected under normal conditions of use.

**Eye Contact:** May cause minor eye irritation.

**Ingestion:** Pharmaceutical. May be harmful if swallowed.

Chronic symptoms: Not available

## Indication of Any Immediate Medical Attention and Special Treatment Needed

If exposed or concerned, get medical advice and attention.

### 5. FIREFIGHTING MEASURES

#### **Extinguishing Media**

Suitable extinguishing media: Not flammable. Use extinguishing media appropriate for surrounding fire.

Unsuitable extinguishing media: None known.

#### **Special Hazards Arising From the Substance or Mixture**

Fire hazard: Not flammable.

**Explosion hazard:** Product itself is not explosive but if dust is generated, dust clouds suspended in air can be explosive.

Reactivity: Hazardous reactions will not occur under normal conditions.

## **Advice for Firefighters**

**Precautionary measures fire:** Exercise caution when fighting any chemical fire.

**Firefighting instructions:** Use water spray or fog for cooling exposed containers.

Protection during firefighting: Do not enter fire area without proper protective equipment, including respiratory protection.

**Hazardous Combustion Products:** Carbon oxides (CO, CO<sub>2</sub>). **Other information:** Refer to Section 9 for flammability properties.

#### 6. ACCIDENTAL RELEASE MEASURES

## Personal Precautions, Protective Equipment and Emergency Procedures

General measures: Avoid all contact with skin, eyes, or clothing. Avoid generating dust.

For Non-Emergency Personnel

Protective equipment: Use appropriate personal protection equipment (PPE).

**Emergency procedures:** Evacuate unnecessary personnel.

For Emergency Personnel

**Protective equipment:** Equip cleanup crew with proper protection.

## **Environmental Precautions**

Prevent entry to sewers and public waters.

## Methods and Material for Containment and Cleaning Up

**Methods for cleaning up:** For small quantities associated with normal therapeutic use, collect spillage and transfer to a closed waste container for disposal. For large or bulk quantities, after absorption with inert material, collect spillage by sweeping up spilled material and place in a labeled, sealed container for proper disposal.

## **Reference to Other Sections**

See heading 8, Exposure Controls and Personal Protection.

31 May 2016 EN (English US) 2/5

#### HANDLING AND STORAGE

#### **Precautions for Safe Handling**

**Patients/Consumers:** Patients should adhere to the instructions provided within the product information insert or product label for appropriate consumer-specific information about this product when used according to the physician's directions.

**Hygiene measures:** This SDS is for a pharmaceutical agent - Handling of this product in its final form presents minimal occupational exposure risk. In an occupational setting, handle in accordance with good industrial hygiene and safety procedures. Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. Use appropriate personal protective equipment when handling and observe good personal hygiene measures after handling.

#### **Conditions for Safe Storage, Including Any Incompatibilities**

Storage conditions: Store in a dry, cool and well-ventilated place. Protect from heat and direct sunlight.

#### Specific End Use(s)

7.

Pharmaceutical. Refer to product insert for usage instructions and product information.

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## **Control Parameters**

Silica, amorphous (7631-86-9)		
USA NIOSH	NIOSH REL (TWA) (mg/m³)	$6 \text{ mg/m}^3$
USA IDLH	US IDLH (mg/m³)	3000 mg/m <sup>3</sup>
Nunavut	OEL TWA (mg/m³)	0.15 mg/m³ (regulated under Silica flour, total mass)
Northwest Territories	OEL TWA (mg/m³)	0.15 mg/m³ (total mass, regulated under Silica flour)
Yukon	OEL TWA (mg/m³)	2 mg/m <sup>3</sup>

#### **Exposure Controls**

**Appropriate engineering controls:** Not generally required. Site-specific risk assessments should be conducted to determine the appropriate exposure control measures. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits.

**Personal protective equipment:** Not generally required. The use of personal protective equipment may be necessary as conditions warrant.

Hand protection: Wear protective gloves made from PVC, neoprene, nitrile, vinyl, or PVC/NBR.

**Eye protection:** In laboratory, medical or industrial settings, or operations in which airborne particulates will be generated, safety glasses with side shields are recommended.

**Skin and body protection:** In laboratory, medical or industrial settings, impervious disposable gloves and protective clothing are recommended if skin contact with drug product is possible.

**Respiratory protection:** When manufacturing or handling product in large quantities and dusts or particulates may be generated, maintain airborne concentrations below recommended limits. Workplace risk assessments should be completed before specifying and implementing respirator usage. NIOSH/MSHA approved respirators for protection should be used if respirators are found to be necessary.

#### 9. PHYSICAL AND CHEMICAL PROPERTIES

## Information on Basic Physical and Chemical Properties

Physical state : Solid

**Appearance** : White film-coated, round tablet

**Odor and Odor Threshold** Not available Not available Relative evaporation rate (butyl acetate=1) Not available Melting/Freezing point Not available **Boiling point** Not available Flash point Not available Not available **Auto-ignition temperature Decomposition Temperature** Not available Flammability (solid, gas) Not available Not available Upper/Lower flammable limit Vapor pressure Not available Relative vapor density at 20 °C Not available Relative density/Specific gravity Not available **Solubility** Not available Log Pow/Kow Not available Viscosity (kinematic, dynamic) Not available **Explosion data** Not available

31 May 2016 EN (English US) 3/5

#### 10. STABILITY AND REACTIVITY

**Reactivity** Hazardous reactions will not occur under normal conditions.

**Chemical Stability** Stable under normal conditions.

<u>Possibility of Hazardous Reactions</u> Hazardous polymerization will not occur.

Conditions to Avoid Direct sunlight. Extremely high or low temperatures. Avoid creating or spreading dust.

**Incompatible Materials** Strong oxidizers. Strong bases. Strong acids. **Hazardous Decomposition Products** Carbon oxides (CO, CO<sub>2</sub>).

#### 11. TOXICOLOGICAL INFORMATION

## Information on Toxicological Effects - Product

Acute toxicity: Not classified LD50 and LC50 Data: Not available

Respiratory or skin sensitization: Not classified

Germ cell mutagenicity: Not classified

**Teratogenicity:** Not available **Carcinogenicity:** Not classified

Specific target organ toxicity (repeated exposure): Not classified

Reproductive toxicity: Not classified

Specific target organ toxicity (single exposure): Not classified

Aspiration hazard: Not classified

<u>Information on Toxicological Effects - Ingredient(s)</u>

#### LD50 and LC50 Data

Silica, amorphous (7631-86-9)		
LD50 oral rat	> 5000 mg/kg	
LD50 dermal rabbit	> 2000 mg/kg	
LC50 inhalation rat (mg/l)	> 2.2 mg/l (Exposure time: 1 h)	
Silica, amorphous (7631-86-9)		
IARC group	3	
Spironolactone (52-01-7)		
IARC group	3	
10	ECOLOGICAL INFORMATION	

## 12. ECOLOGICAL INFORMATION

## **Toxicity**

Silica, amorphous (7631-86-9)	
LC50 fish 1	5000 mg/l (Exposure time: 96 h - Species: Brachydanio rerio [static])
EC50 Daphnia 1	7600 mg/l (Exposure time: 48 h - Species: Ceriodaphnia dubia)
EC50 other aquatic organisms 1	440 mg/l (Exposure time: 72 h - Species: Pseudokirchneriella subcapitata)

## Persistence and Degradability Not available

#### **Bioaccumulative Potential**

Silica, amorphous (7631-86-9)	
BCF fish 1	(no bioaccumulation expected)

## 13. DISPOSAL CONSIDERATIONS

Waste disposal recommendations: Dispose of waste material in accordance with all local, regional, national, provincial, territorial and international regulations. Do not dispose of waste into sewer.

#### 14. TRANSPORT INFORMATION

# In Accordance With ICAO/IATA/DOT/TDG UN Number Not regulated for transport

UN Proper Shipping Name Not regulated for transport

## 15. REGULATORY INFORMATION

#### **US Federal Regulations**

## **Silica, amorphous (7631-86-9)**

Listed on the United States TSCA (Toxic Substances Control Act) inventory

#### Spironolactone (52-01-7)

Listed on the United States TSCA (Toxic Substances Control Act) inventory

## **US State Regulations**

Spironolactone (52-01-7)	
U.S California - Proposition 65 - Carcinogens List	WARNING: This product contains chemicals known to the State of
	California to cause cancer.

31 May 2016 EN (English US) 4/5

## Silica, amorphous (7631-86-9)

- U.S. California Toxic Air Contaminant List (AB 1807, AB 2728)
- U.S. Massachusetts Right To Know List
- U.S. New Jersey Right to Know Hazardous Substance List
- U.S. Pennsylvania RTK (Right to Know) List

## **Canadian Regulations**

Spironolactone Tablets, USP	
WHMIS Classification	Uncontrolled product according to WHMIS classification criteria
Silica amorphous (7631-86-0	

#### Silica, amorphous (7631-86-9)

Listed on the Canadian DSL (Domestic Substances List) inventory.

Listed on the Canadian Ingredient Disclosure List

WHMIS Classification Uncontrolled product according to WHMIS classification criteria

#### Spironolactone (52-01-7)

Listed on Non-Domestic Substances List (NDSL)

This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the MSDS contains all of the information required by CPR.

#### 16. OTHER INFORMATION

**Revision date** : 31 May 2016

**Data sources** : This document has been prepared in accordance with the SDS requirements of the OSHA Hazard

Communication Standard 29 CFR 1910.1200.

Other information : This document has been prepared in accordance with standards for workplace safety. The

precautionary statements and warnings included might not apply in all cases. Your needs may

vary depending on the potential for exposure in your workplace.

#### Party Responsible For The Preparation Of This Document:

Mylan Global Environmental, Health, and Safety Department

Phone Number: 304-599-2595

This SDS has been prepared for occupational exposure and intended to address some end-user concerns; however, patients/consumers are also strongly encouraged to review the product information insert or product label for consumer-specific information about this product. Patients/Consumers: Refer to the package insert or product label for appropriate consumer-specific information about this product when used according to manufacturer's directions. To the best of our knowledge, the information contained herein is accurate. However, neither the above named supplier nor any of its subsidiaries assumes any liability whatsoever for completeness of the information herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.

Mylan NA GHS SDS

31 May 2016 EN (English US) 5/5